DTIC ADA567269: Biomarkers in the Detection of Prostate Cancer in African Americans

📝 Description

All IRBs have been approved by the participating sites and the DOD. Dr. Grizzles laboratory has completed a pilot analysis by Luminex multiplex immunoassay of serum using two panels of biomarkers, cancer biomarkers (e.g., CA19.9) and inflammatory cytokines (e.g., IL- 17a), to identify potential biomarkers that are differentially expressed. Molecular features that are not differentially expressed and for which there are not apparent racial differences will be excluded in future studies to narrow the biomarkers to be evaluated on the larger series of cases. In collaboration with Dr. Clayton Yates at Tuskegee, microRNAs have been identified that apparently vary with race. A study of prostate cancer is now underway to identify microRNAs that are differentially expressed in cancer and that show racial differences. Dr. Gaston's laboratory has completed a pilot analysis of DNA methylation markers that are sensitive to the presence of occult high grade prostate cancer that's been missed due to biopsy sampling error. Our collaborator Rick Kittles and others have shown that cancer-associated DNA methylation marker patterns differ in patients of different racial ancestry. We are now well positioned to utilize our DNA methylation marker field effect test in a comparison of our AA and EA study subjects.